Takeover Bid Rejected — But Is Intertek Still in Play?
Why It Matters
The rejection of EQT’s bid and the strategic review could unlock hidden value, prompting a potential breakup or higher‑priced offer that may substantially boost Intertek’s share price.
Key Takeaways
- •Intertek pivots to higher‑margin, regulation‑driven services for clients
- •Board rejected EQT’s low‑ball takeover; deadline mid‑May for company
- •Strategic review may split testing vs energy divisions
- •Corporate assurance unit shows double‑digit growth; energy lags
- •Shares trade at 16× forward earnings, below five‑year average
Summary
Intertek (ITRK) announced a strategic review after a low‑ball takeover approach from Swedish private‑equity firm EQT was rejected, sparking speculation about a possible split of its testing‑assurance and energy‑infrastructure businesses. The board gave EQT until mid‑May to submit a firm offer, signaling that management believes the company holds more intrinsic value than the current bid reflects. The company, led by long‑time CEO André Lacroix, has been shifting toward higher‑margin, regulation‑driven services such as sustainability and supply‑chain auditing. Recent trading updates show 5.4% like‑for‑like revenue growth, driven by double‑digit expansion in the corporate assurance segment, while the energy division remains flat amid geopolitical headwinds. Leadership changes underscore the new strategic direction: Steve Mockford will assume the chairmanship, and a CFO reshuffle has already taken place. The minerals sub‑segment within energy posted strong double‑digit growth, and the firm continues modest M&A activity despite criticism over limited share buybacks. Valuation remains attractive at roughly 16 times forward earnings, a discount to its five‑year average and peers such as SGS and Bureau Veritas. If the split proceeds or EQT returns with a higher bid, the stock could see significant upside, making Intertek a focal point for investors seeking exposure to resilient testing and certification markets.
Comments
Want to join the conversation?
Loading comments...